- Special Report: Syria's Islamists seize control as moderates dither
- Arizona killer who asked for speedy execution found dead in cell
- Actor James Gandolfini, star of 'The Sopranos,' dies in Italy
- UPDATE 2-Storm Barry heads for Mexico Gulf coast oil installations
- New generation of elite universities rises around the globe
AIDS gels may work, but weakness seen in cocktails
WASHINGTON (Reuters) - Researchers trying to find a way to protect women from the AIDS virus said on Monday they had the first evidence that protective gels might work.
But two studies show that men who take powerful anti-HIV drug cocktails may still pass the virus on in their semen, even if it cannot be found by blood tests.
The studies presented at a meeting of AIDS experts in Canada show slow progress in finding ways to slow the pandemic of deadly human immunodeficiency virus, which infects 33 million people globally and which has killed 25 million.
Dr. Salim Abdool Karim of the Center for the AIDS Program of Research in South Africa and colleagues tested a gel made by Massachusetts-based Indevus Pharmaceuticals called PRO 2000 in a study involving 3,000 women.
They are trying to find a microbicide -- a gel or cream that women and perhaps men can use to protect against the AIDS virus when their partners cannot or will not use a condom.
PRO 2000 reduced the rate of HIV infection by a third, they told the meeting. "This is the first study that now shows that we have a promising candidate," Karim told a news conference at the Conference on Retroviruses in Montreal.
"We do not regard it as a definitive conclusion that PRO 2000 is a microbicide but we certainly view it as very promising."
His team tested another microbicide called BufferGel made by ReProtect Inc, but were unable to find any significant sign that it helped. The study was only designed to show the gels were safe, an especially important issue because other studies have shown would-be microbicides actually raised the risk of infection.
DRUGS AS PROTECTION
Two studies in monkeys showed combinations of Gilead Sciences Inc.'s HIV drug Viread, or tenofovir, with its newer drug emtricitabine, marketed under the brand name Truvada, could protect monkeys from infection with a monkey virus similar to HIV both as a gel or in pills.
Dr. Gerardo Garcia-Lerma and colleagues at the U.S. Centers for Disease Control and Prevention gave Truvada pills to monkeys in an approach called pre-exposure prophylaxis and found the monkeys were protected by a single dose even up to three days before exposure to HIV.
CDC's Drs. Charles Dobard and Walid Heneine treated monkeys with one of two gels, one containing Viread alone and one with both drugs. Either gel worked equally well in protecting the monkeys, they told the meeting.
But two studies showed that men who take drug cocktails known as highly active antiretroviral therapy or HAART can still pass the virus in their semen.
Prameet Sheth of the University of Toronto in Canada and Anne-Genevieve Marcelin of the Pitie-Salpetriere in Paris both found that men whose blood seemed clear of HIV nonetheless had some in their semen.
"I would argue that it is infectious although we don't know what level of virus is required," Sheth told the news conference.
The drug cocktails do not cure AIDS, but drive down levels of the virus to undetectable levels in blood. This helps stop the virus from destroying the immune system and keeps patients healthy.
The hope had been they would reduce the spread of AIDS, and on a population level that may still be true, the researchers told the meeting.
It was not clear why the virus could be found in semen but not in blood but experts know it is impossible to completely suppress the virus.
(Editing by Michael Kahn and Eric Walsh)
- Tweet this
- Share this
- Digg this